Simmons & Simmons is advising Rothschild as sponsor, Deutsche Bank, Panmure Gordon as joint bookrunners, and HSBC as co-lead manager on a £200m rights issue in RPC Group Plc (the international rigid plastic packaging supplier to the food and non-food, consumer and industrial markets) as part of the funding for its proposed €386m euros (£307m) acquisition of Promens Group AS, a leading European manufacturer of rigid plastic packaging products and rigid plastic components, with a growing platform in emerging markets.

Ashurst advised Deutsche Bank in relation to an accelerated bookbuilding offer of 6,180,000 million shares of Amadeus IT Holding, S.A., the Spanish travel software group. The shares represent 1.4 per cent of Amadeus' capital.

The Ashurst finance team was led by Madrid-based partner Juan Hormaechea and London-based partner Jonathan Haines. They were assisted by senior associate James Knight and solicitor Matt Fassnidge.

Clifford Chance has advised the underwriters in connection with the EUR 1 billion capital increase of Telekom Austria AG.

Today, Telekom Austria AG completed its EUR 1 billion capital increase including a rights offering to existing shareholders and a sale to the market of any shares not subscribed by its shareholders.

Addleshaw Goddard's Manchester corporate team has advised Zeus Capital on the £125m IPO of Quantum Pharma on AIM. The pharmaceutical business plans to have a market capitalisation of £125m upon admission to AIM which is expected to take place on 11 December 2014.

Zeus were advised by corporate finance partner Roger Hart and legal directors Duncan Wilson and Shelley McGivern.

Roger Hart commented: "The IPO market has been more subdued than earlier in the year, but this transaction shows that a good business can come to market."

Active Biotech AB (Nasdaq Stockholm) carries out a rights offering of SEK 225 million. Vinge advises Active Biotech. The Vinge team primarily consists of Erik Sjöman (partner, capital markets & public M&A) and associates Christian Lindhé, Ludvig Frithiof and Madelene Eriksson.

The class B shares of Lifco AB (publ) have been admitted to trading on the main market of Nasdaq Stockholm, following an offering to the general public in Sweden and to institutional investors in Sweden and abroad. The price in the offering was SEK 93 per share, corresponding to a market value of all Lifco shares of approximately SEK 8.4 billion.

DLA Piper has advised Australian Securities Exchange-listed REVA Medical, Inc. on the issue of US$25 million of convertible notes and also 8,750,000 options to an international investor consortium.

Headquartered in San Diego, REVA Medical, Inc., is developing a bioresorbable coronary scaffold for cardiovascular disease. The device provides a temporary support and drug supply for an artery after surgery and is naturally absorbed by the body over a period of years.

A Clayton Utz team is advising Australian retailer Godfreys Group Limited (Godfreys) on its proposed Initial Public Offering (IPO) and listing on the Australian Securities Exchange, with an expected market capitalisation on listing of approximately $110.8 million. The prospectus was filed on Monday 25 November with listing on the ASX expected to commence on 10 December.

Medivir AB (publ) (Nasdaq Stockholm) has resolved on a voluntary share redemption programme of SEK 625 million. Vinge advises Medivir. The Vinge team primarily consists of Erik Sjöman (partner, capital markets & public M&A) and Rikard Lindahl.

Travers Smith LLP has advised Benchmark Holdings PLC, the international animal health, technical publishing and sustainability science business, on its £70m fundraising and proposed acquisitions of SalmoBreed and Stofnifskur.